CAMP4 Therapeutics Files for Proposed Initial Public Offering

CAMP4 Therapeutics (CAMP) has submitted a proposal for an initial public offering (IPO).

The company defines itself as a clinical-stage biopharmaceutical organization that is at the forefront of discovering and developing regulatory RNA-based therapeutics. Its goal is to enhance gene expression and restore healthy protein levels to treat a wide array of genetic diseases. Regulatory RNAs, or regRNAs, are crucial for regulating every protein-coding gene, influencing both gene activation and suppression. CAMP4’s innovative approach aims to boost messenger RNA (mRNA) expression by leveraging regRNAs that form localized complexes with transcription factors, thereby controlling gene expression.

The company utilizes its proprietary RNA Actuating Platform (RAP Platform) to efficiently identify and characterize the active regulatory elements responsible for controlling expressed genes, as well as tens of thousands of druggable enhancer and promoter regRNA sequences that govern protein-coding genes. Once a target gene associated with a disease is identified, the RAP Platform is employed to determine the regulating regRNA, leading to the rapid development of novel antisense oligonucleotide (ASO) candidates, which the company refers to as RNA Actuators. These ASOs are designed to bind with the identified regRNA, facilitating the amplification of the target gene’s expression in a specific and controlled manner.

CAMP4 Therapeutics is initially concentrating on metabolic disorders and central nervous system (CNS) diseases with established biological pathways. The company believes its RAP Platform enables the potential to tackle a wide range of genetic diseases where even a slight increase in protein expression could have significant clinical implications.

The underwriting team for the IPO will consist of J.P. Morgan, Leerink Partners, Piper Sandler, and William Blair.